Published in Cancer Res on November 08, 2011
Depleting tumor-specific Tregs at a single site eradicates disseminated tumors. J Clin Invest (2013) 2.77
Immunity, inflammation and cancer: a leading role for adenosine. Nat Rev Cancer (2013) 1.69
Pathogen-specific Treg cells expand early during mycobacterium tuberculosis infection but are later eliminated in response to Interleukin-12. Immunity (2013) 1.24
TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer. Oncoimmunology (2013) 1.22
Th2 type inflammation promotes the gradual progression of HPV-infected cervical cells to cervical carcinoma. Gynecol Oncol (2012) 1.15
Genetics and biology of pancreatic ductal adenocarcinoma. Genes Dev (2016) 1.13
Tumor-infiltrating PD1-Positive Lymphocytes and FoxP3-Positive Regulatory T Cells Predict Distant Metastatic Relapse and Survival of Clear Cell Renal Cell Carcinoma. Transl Oncol (2013) 1.08
Basic principles of tumor-associated regulatory T cell biology. Trends Immunol (2012) 1.05
Breaking immune tolerance by targeting Foxp3(+) regulatory T cells mitigates Alzheimer's disease pathology. Nat Commun (2015) 1.04
Regulatory T cells in radiotherapeutic responses. Front Oncol (2012) 0.98
CTLA4 aptamer delivers STAT3 siRNA to tumor-associated and malignant T cells. J Clin Invest (2014) 0.96
CCR7 expression and intratumoral FOXP3+ regulatory T cells are correlated with overall survival and lymph node metastasis in gastric cancer. PLoS One (2013) 0.88
Patient-tailored modulation of the immune system may revolutionize future lung cancer treatment. BMC Cancer (2012) 0.88
Cancer-produced metabolites of 5-lipoxygenase induce tumor-evoked regulatory B cells via peroxisome proliferator-activated receptor α. J Immunol (2013) 0.88
Adenosine as an endogenous immunoregulator in cancer pathogenesis: where to go? Purinergic Signal (2012) 0.88
Tumor infiltrating lymphocytes (TIL) and prognosis in oral cavity squamous carcinoma: a preliminary study. Oral Oncol (2014) 0.87
Therapeutical measures to control airway tolerance in asthma and lung cancer. Front Immunol (2012) 0.86
Fully human antagonistic antibodies against CCR4 potently inhibit cell signaling and chemotaxis. PLoS One (2014) 0.85
Local expression of interleukin-2 by B16 melanoma cells results in decreased tumour growth and long-term tumour dormancy. Immunology (2013) 0.85
The functional and prognostic implications of regulatory T cells in colorectal carcinoma. J Gastrointest Oncol (2015) 0.85
Humanization of an anti-CCR4 antibody that kills cutaneous T-cell lymphoma cells and abrogates suppression by T-regulatory cells. Mol Cancer Ther (2012) 0.85
Reporter gene imaging of immune responses to cancer: progress and challenges. Theranostics (2012) 0.83
Immune system phenotyping of radiation and radiation combined injury in outbred mice. Radiat Res (2012) 0.82
Suppression of Tregs by anti-glucocorticoid induced TNF receptor antibody enhances the antitumor immunity of interferon-α gene therapy for pancreatic cancer. Cancer Sci (2014) 0.82
The bone marrow of myeloma patients is steadily inhabited by a normal-sized pool of functional regulatory T cells irrespectiveof the disease status. Haematologica (2014) 0.82
Tumor Budding Correlates With the Protumor Immune Microenvironment and Is an Independent Prognostic Factor for Recurrence of Stage I Lung Adenocarcinoma. Chest (2015) 0.82
PD-L1 blockade enhances response of pancreatic ductal adenocarcinoma to radiotherapy. EMBO Mol Med (2016) 0.81
Inhibition of lung metastasis by chemokine CCL17-mediated in vivo silencing of genes in CCR4+ Tregs. J Immunother (2013) 0.80
T Helper Lymphocyte Subsets and Plasticity in Autoimmunity and Cancer: An Overview. Biomed Res Int (2015) 0.80
Depletion of CD4+ CD25+ regulatory T cells promotes CCL21-mediated antitumor immunity. PLoS One (2013) 0.80
Hypoxia-inducible factors in T lymphocyte differentiation and function. A Review in the Theme: Cellular Responses to Hypoxia. Am J Physiol Cell Physiol (2015) 0.80
Combination of SLC administration and Tregs depletion is an attractive strategy for targeting hepatocellular carcinoma. Mol Cancer (2013) 0.79
The fatal alliance of cancer and T cells: How pancreatic tumor cells gather immunosuppressive T cells. Oncoimmunology (2014) 0.79
Ubiquitin-dependent regulation of Foxp3 and Treg function. Immunol Rev (2015) 0.78
Maraviroc decreases CCL8-mediated migration of CCR5(+) regulatory T cells and reduces metastatic tumor growth in the lungs. Oncoimmunology (2016) 0.78
Definitive activation of endogenous antitumor immunity by repetitive cycles of cyclophosphamide with interspersed Toll-like receptor agonists. Oncotarget (2016) 0.78
Regulatory T cells in B-cell-deficient and wild-type mice differ functionally and in expression of cell surface markers. Immunology (2015) 0.77
p38 MAPK-inhibited dendritic cells induce superior antitumour immune responses and overcome regulatory T-cell-mediated immunosuppression. Nat Commun (2014) 0.77
Impaired T-bet-pSTAT1α and perforin-mediated immune responses in the tumoral region of lung adenocarcinoma. Br J Cancer (2015) 0.77
Type I IFN gene delivery suppresses regulatory T cells within tumors. Cancer Gene Ther (2014) 0.77
Cancer as an immune-mediated disease. Immunotargets Ther (2012) 0.77
Non-viral immune electrogene therapy induces potent antitumour responses and has a curative effect in murine colon adenocarcinoma and melanoma cancer models. Gene Ther (2014) 0.77
Enhanced antitumor immunity contributes to the radio-sensitization of ehrlich ascites tumor by the glycolytic inhibitor 2-deoxy-D-glucose in mice. PLoS One (2014) 0.77
Gastrointestinal toxicities of 5-fluorouracil increase the proportion of regulatory T cells in intestinal tract: advantages of alternate-day S-1 administration. Int J Clin Oncol (2015) 0.77
CD4(+)CD25(-)Foxp3(+) T cells play a role in tuberculous hydrothorax rather than malignant hydrothorax. J Transl Med (2015) 0.76
Clinical significance of T-bet, GATA-3, and Bcl-6 transcription factor expression in bladder carcinoma. J Transl Med (2016) 0.76
Repurposing Drugs in Oncology (ReDO)-diclofenac as an anti-cancer agent. Ecancermedicalscience (2016) 0.76
Spontaneous Intestinal Tumorigenesis in Apc (/Min+) Mice Requires Altered T Cell Development with IL-17A. J Immunol Res (2015) 0.76
The Role of Lymphocytes in Radiotherapy-Induced Adverse Late Effects in the Lung. Front Immunol (2016) 0.75
Phenotypic screening reveals TNFR2 as a promising target for cancer immunotherapy. Oncotarget (2016) 0.75
Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4(+) tumor-infiltrating lymphocytes. Oncoimmunology (2016) 0.75
Update on the challenges and recent advances in cancer immunotherapy. Immunotargets Ther (2013) 0.75
Chemokines and their receptors play important roles in the development of hepatocellular carcinoma. World J Hepatol (2015) 0.75
Role of tumor microenvironment in tumorigenesis. J Cancer (2017) 0.75
Ubiquitin ligase A20 regulates p53 protein in human colon epithelial cells. J Biomed Sci (2013) 0.75
Differentiated State of Initiating Tumor Cells Is Key to Distinctive Immune Responses Seen in H-Ras(G12V)-Induced Squamous Tumors. Cancer Immunol Res (2017) 0.75
Cancer immunotherapy: A vaccine from plant virus proteins. Nat Nanotechnol (2015) 0.75
Regulatory T cell subsets in patients with medulloblastoma at diagnosis and during standard irradiation and chemotherapy (PBTC N-11). Cancer Immunol Immunother (2017) 0.75
PD-1 blockade restores impaired function of ex vivo expanded CD8(+) T cells and enhances apoptosis in mismatch repair deficient EpCAM(+)PD-L1(+) cancer cells. Onco Targets Ther (2017) 0.75
Acceleration of pancreatic tumorigenesis under immunosuppressive microenvironment induced by Reg3g overexpression. Cell Death Dis (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 67.34
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol (2006) 9.42
Plasticity of CD4+ T cell lineage differentiation. Immunity (2009) 8.08
Natural innate and adaptive immunity to cancer. Annu Rev Immunol (2011) 7.09
Concomitant tumor immunity to a poorly immunogenic melanoma is prevented by regulatory T cells. J Exp Med (2004) 4.77
Tumour-infiltrating regulatory T cells stimulate mammary cancer metastasis through RANKL-RANK signalling. Nature (2011) 4.57
Metronomic cyclophosphamide regimen selectively depletes CD4+CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother (2006) 4.48
Toll-like receptor 8-mediated reversal of CD4+ regulatory T cell function. Science (2005) 4.32
The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol (2006) 3.84
CD4(+) T cells contribute to the remodeling of the microenvironment required for sustained tumor regression upon oncogene inactivation. Cancer Cell (2010) 3.33
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 2.68
Treatment of advanced tumors with agonistic anti-GITR mAb and its effects on tumor-infiltrating Foxp3+CD25+CD4+ regulatory T cells. J Exp Med (2005) 2.51
Generation and accumulation of immunosuppressive adenosine by human CD4+CD25highFOXP3+ regulatory T cells. J Biol Chem (2009) 2.18
Regulatory T cells in cancer. Adv Cancer Res (2010) 2.02
Clinical use of anti-CD25 antibody daclizumab to enhance immune responses to tumor antigen vaccination by targeting regulatory T cells. Ann N Y Acad Sci (2009) 1.96
Foxp3 expression in human cancer cells. J Transl Med (2008) 1.94
Disruption of CCR5-dependent homing of regulatory T cells inhibits tumor growth in a murine model of pancreatic cancer. J Immunol (2009) 1.75
Antigen-specific Tregs control T cell responses against a limited repertoire of tumor antigens in patients with colorectal carcinoma. J Clin Invest (2009) 1.73
Transient T cell depletion causes regression of melanoma metastases. J Transl Med (2008) 1.61
Recognition of a new ARTC1 peptide ligand uniquely expressed in tumor cells by antigen-specific CD4+ regulatory T cells. J Immunol (2005) 1.43
TLR ligand suppression or enhancement of Treg cells? A double-edged sword in immunity to tumours. Oncogene (2008) 1.41
Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. Mol Ther (2009) 1.25
Depletion of regulatory T cells by anti-GITR mAb as a novel mechanism for cancer immunotherapy. Cancer Immunol Immunother (2010) 1.16
TLR1/TLR2 agonist induces tumor regression by reciprocal modulation of effector and regulatory T cells. J Immunol (2011) 1.13
Harnessing the immune response to treat cancer. Oncogene (2010) 1.11
Toxin-coupled MHC class I tetramers can specifically ablate autoreactive CD8+ T cells and delay diabetes in nonobese diabetic mice. J Immunol (2010) 1.07
Tremelimumab (anti-CTLA4) mediates immune responses mainly by direct activation of T effector cells rather than by affecting T regulatory cells. Clin Immunol (2010) 0.99
Stimulation of the glucocorticoid-induced TNF receptor family-related receptor on CD8 T cells induces protective and high-avidity T cell responses to tumor-specific antigens. J Immunol (2010) 0.96
Methyl gallate exhibits potent antitumor activities by inhibiting tumor infiltration of CD4+CD25+ regulatory T cells. J Immunol (2010) 0.96
Effective immunotherapy of weakly immunogenic solid tumours using a combined immunogene therapy and regulatory T-cell inactivation. Cancer Gene Ther (2010) 0.94
Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity. Immunity (2009) 8.20
A crucial role for interleukin (IL)-1 in the induction of IL-17-producing T cells that mediate autoimmune encephalomyelitis. J Exp Med (2006) 7.87
Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1β in type 2 diabetes. Nat Immunol (2010) 6.64
Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology (2005) 5.75
TLR4 mediates vaccine-induced protective cellular immunity to Bordetella pertussis: role of IL-17-producing T cells. J Immunol (2006) 3.44
Abandon the mouse research ship? Not just yet! Shock (2014) 2.60
Multireplicon genome architecture of Lactobacillus salivarius. Proc Natl Acad Sci U S A (2006) 2.43
CD39+Foxp3+ regulatory T Cells suppress pathogenic Th17 cells and are impaired in multiple sclerosis. J Immunol (2009) 2.30
A pilot study of the immunological effects of high-dose vitamin D in healthy volunteers. Mult Scler (2012) 2.16
Hepatitis C virus-specific Th17 cells are suppressed by virus-induced TGF-beta. J Immunol (2008) 2.04
Caspase-1-processed cytokines IL-1beta and IL-18 promote IL-17 production by gammadelta and CD4 T cells that mediate autoimmunity. J Immunol (2011) 1.98
Toll-like receptor 4-mediated innate IL-10 activates antigen-specific regulatory T cells and confers resistance to Bordetella pertussis by inhibiting inflammatory pathology. J Immunol (2003) 1.96
Infiltration of Th1 and Th17 cells and activation of microglia in the CNS during the course of experimental autoimmune encephalomyelitis. Brain Behav Immun (2010) 1.93
CD4+CD25+ regulatory T cells control innate immune reactivity after injury. J Immunol (2005) 1.89
Electrochemotherapy: aspects of preclinical development and early clinical experience. Ann Surg (2007) 1.85
Pathogen-specific regulatory T cells provoke a shift in the Th1/Th2 paradigm in immunity to infectious diseases. Trends Immunol (2002) 1.85
A prospective study of common bile duct calculi in patients undergoing laparoscopic cholecystectomy: natural history of choledocholithiasis revisited. Ann Surg (2004) 1.83
Induction of autophagy by drug-resistant esophageal cancer cells promotes their survival and recovery following treatment with chemotherapeutics. Autophagy (2011) 1.81
Suppression of antitumor immunity by IL-10 and TGF-beta-producing T cells infiltrating the growing tumor: influence of tumor environment on the induction of CD4+ and CD8+ regulatory T cells. J Immunol (2006) 1.81
Injury primes the innate immune system for enhanced Toll-like receptor reactivity. J Immunol (2003) 1.76
Injury, sepsis, and the regulation of Toll-like receptor responses. J Leukoc Biol (2003) 1.71
CD4 T helper type 1 and regulatory T cells induced against the same epitopes on the core protein in hepatitis C virus-infected persons. J Infect Dis (2002) 1.69
IL-17-producing γδ T cells and innate lymphoid cells. Eur J Immunol (2012) 1.66
Hepatitis C virus non-structural protein 4 suppresses Th1 responses by stimulating IL-10 production from monocytes. Eur J Immunol (2003) 1.60
A protective role for inflammasome activation following injury. Shock (2012) 1.60
Enhanced regulatory T cell activity is an element of the host response to injury. J Immunol (2006) 1.57
Relative contribution of Th1 and Th17 cells in adaptive immunity to Bordetella pertussis: towards the rational design of an improved acellular pertussis vaccine. PLoS Pathog (2013) 1.54
Gastric motor dysfunction: is eosinophilic mural gastritis a causative factor? Eur J Gastroenterol Hepatol (2005) 1.54
Improved luciferase tagging system for Listeria monocytogenes allows real-time monitoring in vivo and in vitro. Appl Environ Microbiol (2007) 1.54
CD200 ligand receptor interaction modulates microglial activation in vivo and in vitro: a role for IL-4. J Neurosci (2007) 1.51
Inflammasome activation by adenylate cyclase toxin directs Th17 responses and protection against Bordetella pertussis. J Immunol (2010) 1.48
Influence of gastrointestinal commensal bacteria on the immune responses that mediate allergy and asthma. J Allergy Clin Immunol (2011) 1.47
Retinoic acid expression associates with enhanced IL-22 production by γδ T cells and innate lymphoid cells and attenuation of intestinal inflammation. J Exp Med (2013) 1.47
Culture-independent analysis of the gut microbiota in colorectal cancer and polyposis. Environ Microbiol (2008) 1.42
Commonality and differences in leukocyte gene expression patterns among three models of inflammation and injury. Physiol Genomics (2005) 1.40
Depletion of NK cells results in disseminating lethal infection with Bordetella pertussis associated with a reduction of antigen-specific Th1 and enhancement of Th2, but not Tr1 cells. Eur J Immunol (2004) 1.39
Infection with a helminth parasite attenuates autoimmunity through TGF-beta-mediated suppression of Th17 and Th1 responses. J Immunol (2009) 1.39
High resolution in vivo bioluminescent imaging for the study of bacterial tumour targeting. PLoS One (2012) 1.36
Analysis of factorial time-course microarrays with application to a clinical study of burn injury. Proc Natl Acad Sci U S A (2010) 1.33
Inhibition of ERK MAPK suppresses IL-23- and IL-1-driven IL-17 production and attenuates autoimmune disease. J Immunol (2009) 1.32
Increased CD4+ CD25+ T regulatory cell activity in trauma patients depresses protective Th1 immunity. Ann Surg (2006) 1.31
Lack of interleukin-1 receptor I (IL-1RI) protects mice from high-fat diet-induced adipose tissue inflammation coincident with improved glucose homeostasis. Diabetes (2011) 1.30
Dietary synbiotics reduce cancer risk factors in polypectomized and colon cancer patients. Am J Clin Nutr (2007) 1.26
Interaction between the innate and adaptive immune systems is required to survive sepsis and control inflammation after injury. Shock (2003) 1.25
Adenylate cyclase toxin from Bordetella pertussis synergizes with lipopolysaccharide to promote innate interleukin-10 production and enhances the induction of Th2 and regulatory T cells. Infect Immun (2004) 1.25
Attenuating regulatory T cell induction by TLR agonists through inhibition of p38 MAPK signaling in dendritic cells enhances their efficacy as vaccine adjuvants and cancer immunotherapeutics. J Immunol (2008) 1.25
Activation of p38 plays a pivotal role in the inhibitory effect of lipopolysaccharide and interleukin-1 beta on long term potentiation in rat dentate gyrus. J Biol Chem (2003) 1.24
Cholera toxin promotes the induction of regulatory T cells specific for bystander antigens by modulating dendritic cell activation. J Immunol (2003) 1.24
Bacterial DNA within granulomas of patients with Crohn's disease--detection by laser capture microdissection and PCR. Am J Gastroenterol (2004) 1.21
Role of interleukin-4 in regulation of age-related inflammatory changes in the hippocampus. J Biol Chem (2004) 1.20
Linking the "two-hit" response following injury to enhanced TLR4 reactivity. J Leukoc Biol (2004) 1.20
Autophagy regulates IL-23 secretion and innate T cell responses through effects on IL-1 secretion. J Immunol (2012) 1.19
IL-27 mediates the response to IFN-β therapy in multiple sclerosis patients by inhibiting Th17 cells. Brain Behav Immun (2011) 1.18
Enhanced TLR4 reactivity following injury is mediated by increased p38 activation. J Leukoc Biol (2005) 1.18
Trauma equals danger--damage control by the immune system. J Leukoc Biol (2012) 1.15
Trauma-hemorrhage induces depressed splenic dendritic cell functions in mice. J Immunol (2006) 1.15
Stable plastid transformation in lettuce (Lactuca sativa L.). Plant Mol Biol (2005) 1.14
Role of the VHL (von Hippel-Lindau) gene in renal cancer: a multifunctional tumour suppressor. Biochem Soc Trans (2008) 1.13
Dendritic cells and other innate determinants of T helper cell polarisation. Trends Immunol (2013) 1.13
Conjugated linoleic acid suppresses NF-kappa B activation and IL-12 production in dendritic cells through ERK-mediated IL-10 induction. J Immunol (2005) 1.11
Orally administered bifidobacteria as vehicles for delivery of agents to systemic tumors. Mol Ther (2010) 1.11
Modulation of T cell and innate immune responses by retinoic Acid. J Immunol (2014) 1.10
TLR based therapeutics. Curr Opin Pharmacol (2011) 1.10
Burn injury promotes antigen-driven Th2-type responses in vivo. J Immunol (2003) 1.09
Bordetella pertussis expresses a functional type III secretion system that subverts protective innate and adaptive immune responses. Infect Immun (2008) 1.09
Decreased neuronal CD200 expression in IL-4-deficient mice results in increased neuroinflammation in response to lipopolysaccharide. Brain Behav Immun (2009) 1.09
Successful application of targeted electrochemotherapy using novel flexible electrodes and low dose bleomycin to solid tumours. Cancer Lett (2005) 1.09
Immunotherapy with PI3K inhibitor and Toll-like receptor agonist induces IFN-γ+IL-17+ polyfunctional T cells that mediate rejection of murine tumors. Cancer Res (2011) 1.08
Mesenchymal stromal cells improve survival during sepsis in the absence of heme oxygenase-1: the importance of neutrophils. Stem Cells (2013) 1.08
Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production. J Immunol (2011) 1.08
Induction of regulatory cells by helminth parasites: exploitation for the treatment of inflammatory diseases. Immunol Rev (2014) 1.08
Effects of cholera toxin on innate and adaptive immunity and its application as an immunomodulatory agent. J Leukoc Biol (2004) 1.07
Injury enhances resistance to Escherichia coli infection by boosting innate immune system function. J Immunol (2008) 1.06
Prostate stem cell antigen DNA vaccination breaks tolerance to self-antigen and inhibits prostate cancer growth. Mol Ther (2009) 1.05
Bacteria as vectors for gene therapy of cancer. Bioeng Bugs (2011) 1.05
Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 production. EMBO Rep (2010) 1.05
Staphylococcus aureus infection of mice expands a population of memory γδ T cells that are protective against subsequent infection. J Immunol (2014) 1.05
Autophagy and inflammatory diseases. Immunol Cell Biol (2013) 1.04
A novel Listeria monocytogenes-based DNA delivery system for cancer gene therapy. Hum Gene Ther (2010) 1.03
IFN-γ Production by amyloid β-specific Th1 cells promotes microglial activation and increases plaque burden in a mouse model of Alzheimer's disease. J Immunol (2013) 1.03
Dietary saturated fatty acids prime the NLRP3 inflammasome via TLR4 in dendritic cells-implications for diet-induced insulin resistance. Mol Nutr Food Res (2012) 1.02
A novel anti-inflammatory role of NCAM-derived mimetic peptide, FGL. Neurobiol Aging (2008) 1.00
Bordetella pertussis adenylate cyclase toxin modulates innate and adaptive immune responses: distinct roles for acylation and enzymatic activity in immunomodulation and cell death. J Immunol (2005) 1.00
Platelet depletion in mice increases mortality after thermal injury. Blood (2006) 1.00
Adenylate cycalse toxin of Bordetella pertussis inhibits TLR-induced IRF-1 and IRF-8 activation and IL-12 production and enhances IL-10 through MAPK activation in dendritic cells. J Leukoc Biol (2008) 1.00
Caspase-1-processed IL-1 family cytokines play a vital role in driving innate IL-17. Cytokine (2011) 0.97
Osteoarthritis-associated basic calcium phosphate crystals induce pro-inflammatory cytokines and damage-associated molecules via activation of Syk and PI3 kinase. Clin Immunol (2012) 0.97
Tumour targeting with systemically administered bacteria. Curr Gene Ther (2010) 0.97
Burn injury induces an early activation response by lymph node CD4+ T cells. Shock (2006) 0.97
Can non-viral technologies knockdown the barriers to siRNA delivery and achieve the next generation of cancer therapeutics? Biotechnol Adv (2011) 0.97
Proinflammatory responses in the murine brain after intranasal delivery of cholera toxin: implications for the use of AB toxins as adjuvants in intranasal vaccines. J Infect Dis (2005) 0.96
Laparoscopic lavage for perforated diverticulitis: a population analysis. Dis Colon Rectum (2012) 0.96
Bcr-Abl reduces endoplasmic reticulum releasable calcium levels by a Bcl-2-independent mechanism and inhibits calcium-dependent apoptotic signaling. Blood (2006) 0.95
Therapeutic potential of targeting IL-17. Nat Immunol (2012) 0.95
Use of intracellular cytokine staining and bacterial superantigen to document suppression of the adaptive immune system in injured patients. Ann Surg (2003) 0.94
TLR, NLR Agonists, and Other Immune Modulators as Infectious Disease Vaccine Adjuvants. Curr Infect Dis Rep (2010) 0.93